References |
1 |
Cisplatin was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
|
2 |
Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
|
3 |
Cytotoxicity, accumulation, and efflux of cisplatin and its metabolites in human ovarian carcinoma cells
|
4 |
Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther. 2008 Oct;7(10):3247-55.
|
5 |
GSTA4 mediates reduction of cisplatin ototoxicity in female mice. Nat Commun. 2019 Sep 12;10(1):4150.
|
6 |
Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43.
|
7 |
Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer. 2000 Mar 15;85(6):777-81.
|
8 |
Cisplatin reduces Brucella melitensis-infected cell number by inducing apoptosis, oxidant and pro-inflammatory cytokine production. Res Vet Sci. 2010 Apr;88(2):218-26.
|
9 |
PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
|